A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study
So-Ngern A, Jirajariyavej S, Thuncharoon H, Khunthupat N, Chantarojanasiri T and Montakantikul P. (2023). A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study. Clinical and Translational Science, 2023(00), 1-10. https://doi.org/10.1111/cts.13665